ARAline Renneville

Aline Renneville

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aline Renneville has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 March 2016
      • Vol. 94  (3) , 190-7

    Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR.

    by Emna Abdelhamid, Sawsen Besbes, Aline Renneville, Olivier Nibourel, Nathalie Helevaut, Claude Preudhomme, Zohra Soua

    With the growing importance of minimal residual disease (MRD) monitoring and the recent discover of IDH mutations in acute myeloid leukemia (AML), the quantification of this molecular marker provides the possibility to monitor the disease progression and the therapy efficacy. The aim of this study is to assess the MRD in AML for the first time with IDH1 and IDH2 gene mutations in 15 AML patients. We have screened R132 IDH1, R140 IDH2 and R172 IDH2 mutations by PCR amplification and direct sequencing and we have quantified them for the first time by RQ-PCR using reverse primers modified by an LNA. A good sensitivity has been obtained. MRD rates obtained by LNA-RQ-PCR were used to draw kinetics of the disease evolution during the follow-up. IDH1/2 Results were compared to NPM1 mutation and WT1 over expression and have showed coherent kinetic between MRD rates in 7/11 cases. For the rest, the direct sequencing and the high resolution melting (HRM) assay have confirmed the quantification Results in diagnosis but not in residual samples. Some optimization will be necessary to improve the mutated allele amplification. The LNA-RQ-PCR might be an easy and less cost method used in a small laboratory for myeloid leukemia MRD assessment using IDH1/2 mutations.


  • Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group

    by Thomas Smol, Olivier Nibourel, Alice Marceau-Renaut, Karine Celli-Lebras, Céline Berthon, Bruno Quesnel, Nicolas Boissel, Christine Terré, Xavier Thomas, Sylvie Castaigne, et al.


  • UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21)

    by Nicolas Duployez, Jean-Baptiste Micol, Nicolas Boissel, Arnaud Petit, Sandrine Geffroy, Maxime Bucci, Hélène Lapillonne, Aline Renneville, Guy Leverger, Norbert Ifrah, et al.


  • Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1‐RUNX1T1 fusion quantification on genomic DNA

    by Nicolas Duployez, Olivier Nibourel, Alice Marceau‐Renaut, Christophe Willekens, Nathalie Helevaut, Aurélie Caillault, Céline Villenet, Karine Celli‐Lebras, Nicolas Boissel, Eric Jourdan, et al.

    Although acute myeloid leukemia (AML) with t(8;21) belongs to the favorable risk AML subset, relapse incidence may reach 30% in those patients. RUNX1‐RUNX1T1 fusion transcript is a well‐established marker for minimal residual disease (MRD) monitoring. In this study, we investigated the feasibility and performances of RUNX1‐RUNX1T1 DNA as MRD marker in AML with t(8;21). In 17/22 patients with t(8;21)‐positive AML treated in the French CBF‐2006 trial, breakpoints in RUNX1 and RUNX1T1 were identified using long‐range PCR followed by next‐generation sequencing. RUNX1‐RUNX1T1 DNA quantification was performed by real‐time quantitative PCR using patient‐specific primers and probe. MRD levels were evaluated in 71 follow‐up samples from 16 patients, with a median of four samples [range 2–7] per patient. RUNX1 breakpoints were located in intron 5 in all cases. RUNX1T1 breakpoints were located in intron 1b in 15 cases and in intron 1a in two cases. RUNX1‐RUNX1T1 MRD levels measured on DNA and RNA were strongly correlated (r = 0.8, P < 0.0001). Discordant MRD results were observed in 10/71 (14%) of the samples: in three samples from two patients who relapsed, RUNX1‐RUNX1T1 was detectable only on DNA, while RUNX1‐RUNX1T1 was detectable only on RNA in seven samples. MRD monitoring on genomic DNA is feasible, but with sensitivity variations depending on the patient breakpoint sequence and the qPCR assay efficiency. Although interpretation of the results is easier because it is closely related to the number of leukemic cells, this method greatly increases time, cost and complexity, which limits its interest in routine practice. Am. J. Hematol. 89:610–615, 2014.